Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial
Charles S. Fuchs(University of Southern California), Francesco Di Costanzo, Fidel David Huitzil Melendez, Katriina Peltola, Alfredo Falcone(Azienda Ospedaliero-Universitaria Careggi), Kohei Shitara(National Cancer Center Hospital East), Alexander Luft, Mayukh Das(Eli Lilly (United States)), Zev A. Wainberg(University of California, Los Angeles), Gunnar Folprecht, Roberto Carlesi(Eli Lilly (Italy)), Alejandro Molina Alavez, Judit Kocsis(Bács-Kiskun Megyei Kórház), Rubén Dario Kowalyszyn, María Alsina(Vall d'Hebron Hospital Universitari), Ian Chau(Royal Marsden NHS Foundation Trust), Nina Karaseva, G. Bodoky(Unified Szent István and Szent László Hospital), Tomasz Sarosiek, David H. Ilson(Memorial Sloan Kettering Cancer Center), Ayman Madi, Peter Bono(Dana-Farber Cancer Institute), Sara Lonardi(Istituto Oncologico Veneto), Jill Lacy(Smilow Cancer Hospital), Ji Lin(Eli Lilly (United States)), Susanna Hegewisch‐Becker, Baruch Brenner(Rabin Medical Center), Andràs Csilla, Cardellino Giovanni Gerardo, Tibor Csőszi, Per Pfeiffer(University of Southern Denmark), Daisuke Takahari(The Cancer Institute Hospital), Naotoshi Sugimoto(Osaka International Cancer Institute), Salah‐Eddin Al‐Batran(Goethe University Frankfurt), Wasat Mansoor(The Christie NHS Foundation Trust), Maria Di Bartolomeo(Fondazione IRCCS Istituto Nazionale dei Tumori), Georgina Garnica Jaliffe, Светлана Проценко, Michel Ducreux(Université Paris-Saclay), Manish A. Shah(NewYork–Presbyterian Hospital), Peter C. Enzinger(Dana-Farber Cancer Institute), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Giuseppe Aprile(Ospedale Santa Maria della Misericordia di Udine), Carlos Alberto Hernández, David Ferry(Eli Lilly (United States)), Guillermo Ariel Mendez(Fundacion Favaloro Hospital Universitario), Elżbieta Wójcik, Vera Gorbounova(Russian Cancer Research Center NN Blokhin), Hubert Ayala, Ferdinando De Vita(University of Campania "Luigi Vanvitelli")
Cited by 282
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k